Citations (69)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Craig I. Coleman, Thomas J. Bunz & Veronica Ashton. (2022) Adherence and persistence to rivaroxaban in non-valvular atrial fibrillation patients receiving 30- or 90-day supply prescription fills. Current Medical Research and Opinion 38:1, pages 19-26.
Read now
Read now
Steven Deitelzweig, Manuela Di Fusco, Amiee Kang, Mirko Savone, Ruth Mokgokong, Allison Keshishian, Cynthia Gutierrez & Joseph C. Cappelleri. (2021) Real-world persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis. Current Medical Research and Opinion 37:6, pages 891-902.
Read now
Read now
Li Chen, Chao Li, Nan Huo, Ahmed Ullah Mishuk, Richard A. Hansen, Ilene Harris, Zippora Kiptanui & Jingjing Qian. (2020) Oral generic tacrolimus initiation and substitution in the Medicaid population: a new user cohort study. Current Medical Research and Opinion 36:9, pages 1533-1540.
Read now
Read now
Anjana Mohan, Matthew A. Wanat & Susan M. Abughosh. (2019) Medication taking behaviors in patients taking warfarin versus direct oral anticoagulants: A systematic review. Expert Review of Cardiovascular Therapy 17:6, pages 427-434.
Read now
Read now
Jean-Baptiste Briere, Kevin Bowrin, Craig Coleman, Laurent Fauchier, Pierre Levy, Kerstin Folkerts, Mondher Toumi, Vanessa Taieb, Aurélie Millier & Olivia Wu. (2019) Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review. Expert Review of Pharmacoeconomics & Outcomes Research 19:1, pages 27-36.
Read now
Read now
A. John Camm & Keith A. A. Fox. (2018) Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban. Current Medical Research and Opinion 34:11, pages 1945-1957.
Read now
Read now
Ylenia Ingrasciotta, Salvatore Crisafulli, Valeria Pizzimenti, Ilaria Marcianò, Anna Mancuso, Giuseppe Andò, Salvatore Corrao, Piera Capranzano & Gianluca Trifirò. (2018) Pharmacokinetics of new oral anticoagulants: implications for use in routine care. Expert Opinion on Drug Metabolism & Toxicology 14:10, pages 1057-1069.
Read now
Read now
Maartje S. Jacobs, Jeroen F. Schouten, Pieter T. de Boer, Mikael Hoffmann, Lars-Åke Levin & Maarten J. Postma. (2018) Secondary adherence to non-vitamin-K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands. Current Medical Research and Opinion 34:10, pages 1839-1847.
Read now
Read now
Walter Ageno, Jan Beyer-Westendorf & Andrea Rubboli. (2017) Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation. Expert Opinion on Pharmacotherapy 18:13, pages 1325-1332.
Read now
Read now
Gonzalo Barón-Esquivias, Francisco Marín & Marcelo Sanmartín Fernandez. (2017) Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice. Expert Review of Cardiovascular Therapy 15:5, pages 403-413.
Read now
Read now
Masatsugu Hori, Shunya Ikeda, Ken Okumura, Shinya Matsuda, Yukihiro Koretsune, Calypso Montouchet, Emi Watanabe-Fujinuma, Thomas Evers, Bruno Rossi, Lewis Ruff & Jean-Baptiste Briere. (2016) Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan. Journal of Medical Economics 19:9, pages 889-899.
Read now
Read now
Paolo Prandoni. (2015) Adherence to the novel oral anticoagulants: an unmet need. Current Medical Research and Opinion 31:12, pages 2175-2177.
Read now
Read now
Mikhail S Dzeshka & Gregory YH Lip. (2015) Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Expert Opinion on Pharmacotherapy 16:17, pages 2661-2678.
Read now
Read now
Gines Escolar, Xavier Carne & Eduardo Arellano-Rodrigo. (2015) Dosing of rivaroxaban by indication: getting the right dose for the patient. Expert Opinion on Drug Metabolism & Toxicology 11:10, pages 1665-1677.
Read now
Read now
Gonzalo Barón-Esquivias, Francisco Fernández-Avilés, Felipe Atienza, Pablo Pastor Pueyo, Rocío Toro & Marcelo Sanmartín Fernández. (2015) Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation. Expert Review of Cardiovascular Therapy 13:4, pages 341-353.
Read now
Read now
Articles from other publishers (54)
Roberto Cemin & Riccardo Cappato. (2023) Lessons derived from post authorisation safety studies (ETNA-AF and XANTUS) on once daily direct oral anticoagulants for atrial fibrillation. International Journal of Cardiology, pages 131618.
Crossref
Crossref
Seung-Kee Min, Ji-Sun Kim, Jang Yong Kim, Ui Jun Park, Taehoon Lee, Jin Mo Kang, Sun Cheol Park, Won-Il Choi, Ki-Hyuk Park & Martin Gebel. (2022) Characteristics and Effect of Rivaroxaban on Venous Thromboembolism in Korean Patients Compared to Western Population: A Subgroup Analysis from XALIA(-LEA) Study. Vascular Specialist International 38.
Crossref
Crossref
Mirela Marioara Toma, Simona Gabriela Bungau, Delia Mirela Tit, Madalina Ioana Moisi, Cristiana Bustea, Cosmin Mihai Vesa, Tapan Behl, Manuela Stoicescu, Cristina Mihaela Brisc, Lavinia Anamaria Purza, Daniela Gitea & Camelia Cristina Diaconu. (2022) Use of anticoagulant drugs in patients with atrial fibrillation. Does adherence to therapy have a prognostic impact?. Biomedicine & Pharmacotherapy 150, pages 113002.
Crossref
Crossref
Amol D Dhamane, Inmaculada Hernandez, Manuela Di Fusco, Cynthia Gutierrez, Mauricio Ferri, Cristina Russ, Wan-Lun Tsai, Birol Emir, Huseyin Yuce & Allison Keshishian. (2021) Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA. American Journal of Cardiovascular Drugs 22:3, pages 333-343.
Crossref
Crossref
Monika Kozieł, Michał Mazurek, Christine Teutsch, Hans-Christoph Diener, Sergio J. Dubner, Jonathan L. Halperin, Chang-Sheng Ma, Kenneth J. Rothman, Axel Brandes, Miney Paquette, Kristina Zint, Lionel Riou França, Shihai Lu, Dorothee B. Bartels, Menno V. Huisman & Gregory Y. H. Lip. (2020) Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up. Journal of Clinical Medicine 9:6, pages 1969.
Crossref
Crossref
Aya F. OzakiAustin S. ChoiQuan T. LeDennis T. KoJanet K. HanSandy S. ParkCynthia A. Jackevicius. (2020) Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes 13:3.
Crossref
Crossref
Hyeongsoo Kim, Young Soo Lee, Tae-Hoon Kim, Myung-Jin Cha, Jung Myung Lee, Junbeom Park, Jin-Kyu Park, Ki-Woon Kang, Jaemin Shim, Jae-Sun Uhm, Hyung Wook Park, Eue-Keun Choi, Jin-Bae Kim, Changsoo Kim, Jun Kim & Boyoung Joung. (2020) A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF). The Korean Journal of Internal Medicine 35:1, pages 99-108.
Crossref
Crossref
Hyun Su Ha, Joongmin Kim, Young Soo Lee, Tae-Hoon Kim, Jung Myung Lee, Junbeom Park, Jin-Kyu Park, Ki-Woon Kang, Jaemin Shim, Jae-Sun Uhm, Hyung Wook Park, Myung-Jin Cha, Eue-Keun Choi, Jun Kim, Jin-Bae Kim, Changsoo Kim & Boyoung Joung. (2020) Current Anticoagulant Usage Patterns and Determinants in Korean Patients with Nonvalvular Atrial Fibrillation. Yonsei Medical Journal 61:2, pages 120.
Crossref
Crossref
O. D. OstroumovaA. I. Kochetkov, S. P. Korchagina, T. M. OstroumovaM. S. Chernyaeva & A. A. Kirichenko. (2019) Anticoagulant Therapy as a Tool for the Prevention of Cognitive Impairment Associated with Atrial Fibrillation. Rational Pharmacotherapy in Cardiology 15:5, pages 713-724.
Crossref
Crossref
Chandrasekar Gopalakrishnan, Sebastian Schneeweiss, Dorothee B. Bartels, Kristina Zint, Adrian Santiago Ortiz & Krista F. Huybrechts. (2019) Evaluating utilization patterns of oral anticoagulants in routine care. Journal of Thrombosis and Haemostasis 17:7, pages 1033-1043.
Crossref
Crossref
Yuliya P. Skirdenko, Nikolay A. Nikolaev, Maria А. Livzan & Anton V. Ershov. (2019) Anticoagulant Therapy for Atrial Fibrillation in Real Practice: Problems and Prospects. Annals of the Russian academy of medical sciences 74:2, pages 98-107.
Crossref
Crossref
Josephine Gibson & Stephanie Jones. 2019. Stroke Nursing. Stroke Nursing
53
74
.
Jin-Kyu Park, Jun Kim, Yong Soo Baek, So-Ryoung Lee, You Mi Hwang, Tae-Hoon Kim, Dae In Lee, Ki Hong Lee, Jaemin Shim & Boyoung Joung. (2019) 2018 KHRS Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Korean Patients with Atrial Fibrillation: How to Initiate and Organize the Follow-up. The Korean Journal of Medicine 94:1, pages 17-39.
Crossref
Crossref
Paolo Verdecchia, Antonio D’Onofrio, Vincenzo Russo, Francesco Fedele, Francesco Adamo, Giulia Benedetti, Fabio Ferrante, Corrado Lodigiani, Francesco Paciullo, Adolfo Aita, Claudia Bartolini, Maria Gabriella Molini, Andrea Di Lenarda, Carmine Mazzone, Lorenza Scotti, Elena Paola Lanati & Arianna Iorio. (2019) Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study. Journal of Cardiovascular Medicine 20:2, pages 66-73.
Crossref
Crossref
Hyunmee Kim, Hyeongsoo Kim, Seong-Kyung Cho, Jin-Bae Kim, Boyoung Joung & Changsoo Kim. (2019) Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation. Korean Circulation Journal 49:3, pages 252.
Crossref
Crossref
Shahrzad Salmasi, Leanne Kwan, Jenny MacGillivray, Nick Bansback, Mary A. De Vera, Arden R. Barry, Mark J. Harrison, Jason Andrade, Larry D. Lynd & Peter Loewen. (2019) Assessment of atrial fibrillation patients' education needs from patient and clinician perspectives: A qualitative descriptive study. Thrombosis Research 173, pages 109-116.
Crossref
Crossref
Ameenathul M. Fawzy & Gregory Y.H. Lip. (2019) Anticoagulation in elderly patients with nonvalvular atrial fibrillation: A balancing act. Heart Rhythm 16:1, pages 38-40.
Crossref
Crossref
Jean Dallongeville, Frédéric Sacher, Stéphane Bouée, Corinne Emery, Isabelle Bureau, Julie Gourmelen & Laurent Fauchier. (2018) Xafran, a drug utilization study of rivaroxaban in stroke prevention in atrial fibrillation in France using a claim database. Therapies 73:6, pages 449-460.
Crossref
Crossref
A. V. FedoseenkoS. A. ZeninO. V. KononenkoO. V. PyataevaY. E. Voskoboyniokov. (2018) RIVOROXABAN IN PATIENTS WITH TYPE I ATRIAL FLUTTER: EFFECTIVENESS, SAFETY AND COMPLIANCE. Complex Issues of Cardiovascular Diseases 7:3, pages 44-55.
Crossref
Crossref
Kathrin I. Foerster, Andrea Huppertz, Andreas D. Meid, Oliver J. Müller, Timolaos Rizos, Lisa Tilemann, Walter E. Haefeli & Jürgen Burhenne. (2018) Dried-Blood-Spot Technique to Monitor Direct Oral Anticoagulants: Clinical Validation of a UPLC–MS/MS-Based Assay. Analytical Chemistry 90:15, pages 9395-9402.
Crossref
Crossref
Mariano de la Figuera, Sergio Cinza, Nuria Marín, Isabel Egocheaga & Miguel Angel Prieto. (2018) Perfil clínico de pacientes con fibrilación auricular tratados con anticoagulantes orales de acción directa atendidos en atención primaria. Estudio SILVER-AP. Atención Primaria 50:6, pages 359-367.
Crossref
Crossref
Jan Steffel, Peter Verhamme, Tatjana S Potpara, Pierre Albaladejo, Matthias Antz, Lien Desteghe, Karl Georg Haeusler, Jonas Oldgren, Holger Reinecke, Vanessa Roldan-Schilling, Nigel Rowell, Peter Sinnaeve, Ronan Collins, A John Camm, Hein Heidbüchel, Gregory Y H Lip, Jeffrey Weitz, Laurent Fauchier, Deirdre Lane, Giuseppe Boriani, Andreas Goette, Roberto Keegan, Robert MacFadyen, Chern-En Chiang, Boyoung Joung & Wataru Shimizu. (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal 39:16, pages 1330-1393.
Crossref
Crossref
Satoshi Ogawa, Kazuo Minematsu, Takanori Ikeda, Takanari Kitazono, Jyoji Nakagawara, Susumu Miyamoto, Yuji Murakawa, Yohei Ohashi, Makiko Takeichi, Yutaka Okayama, Satoshi Yamanaka & Lyo Inuyama. (2018)
Design and baseline characteristics of the Xarelto Post‐Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (
XAPASS
)
. Journal of Arrhythmia 34:2, pages 167-175.
Crossref
Crossref
RA Hansen, J Qian, RL Berg, JG Linneman, E Seoane-Vazquez, S Dutcher, S Raofi, CD Page & PL Peissig. (2018) Comparison of Outcomes Following a Switch From a Brand to an Authorized Versus Independent Generic Drug. Clinical Pharmacology & Therapeutics 103:2, pages 310-317.
Crossref
Crossref
Giavanna Russo-Alvarez, Kathryn A. Martinez, Megan Valente, James Bena, Bo Hu, Jennifer Luxenburg, Alexander Chaitoff, Catherine Ituarte, Andrei Brateanu & Michael B. Rothberg. (2017) Thromboembolic and Major Bleeding Events With Rivaroxaban Versus Warfarin Use in a Real-World Setting. Annals of Pharmacotherapy 52:1, pages 19-25.
Crossref
Crossref
Géric Maura, Cécile Billionnet, François Alla, Joshua J. Gagne & Antoine Pariente. (2018) Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38:1, pages 6-18.
Crossref
Crossref
Faye L. Norby, Lindsay G.S. Bengtson, Pamela L. Lutsey, Lin Y. Chen, Richard F. MacLehose, Alanna M. Chamberlain, Ian Rapson & Alvaro Alonso. (2017) Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation. BMC Cardiovascular Disorders 17:1.
Crossref
Crossref
Jingwen Tan, Sunjae Bae, Jodi B. Segal, Junya Zhu, Dorry L. Segev, G. Caleb Alexander & Mara McAdams-DeMarco. (2017) Treatment of atrial fibrillation with warfarin among older adults with end stage renal disease. Journal of Nephrology 30:6, pages 831-839.
Crossref
Crossref
Faye L Norby & Alvaro Alonso. (2017) Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation. Journal of Comparative Effectiveness Research 6:6, pages 549-560.
Crossref
Crossref
JaeJin AnFang NiuChengyi ZhengNazia RashidRobert A. MendesDiana DillsLien VoPrianka SinghAmanda BrunoDaniel T. LangPaul T. LeKristin P. JazdzewskiGustavus ArandaJr.Jr.. (2017) Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System. Journal of Managed Care & Specialty Pharmacy 23:6, pages 700-712.
Crossref
Crossref
Ekta Y. Pandya & Beata Bajorek. (2016) Factors Affecting Patients’ Perception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants. The Patient - Patient-Centered Outcomes Research 10:2, pages 163-185.
Crossref
Crossref
Andreas Zirlik & Christoph Bode. (2016) Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. Journal of Thrombosis and Thrombolysis 43:3, pages 365-379.
Crossref
Crossref
Vincenzo Russo, Anna Rago, Riccardo Proietti, Federica Di Meo, Andrea Antonio Papa, Paolo Calabrò, Antonio D’Onofrio, Gerardo Nigro & Ahmed AlTurki. (2016) Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Therapeutic Advances in Drug Safety 8:2, pages 67-75.
Crossref
Crossref
Valeria Raparelli, Marco Proietti, Roberto Cangemi, Gregory Y. H. Lip, Deirdre A. Lane & Stefania Basili. (2017) Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Thrombosis and Haemostasis 117:02, pages 209-218.
Crossref
Crossref
Andreas Goette & Matthias Hammwöhner. (2016) How important it is for therapy adherence to be once a day?. European Heart Journal Supplements 18:suppl I, pages I7-I12.
Crossref
Crossref
Jeff R. Schein, C. Michael White, Winnie W. Nelson, Jeffrey Kluger, Elizabeth S. Mearns & Craig I. Coleman. (2016) Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. Thrombosis Journal 14:1.
Crossref
Crossref
Alpesh Amin & Joel C. Marrs. (2016) Direct Oral Anticoagulants for the Management of Thromboembolic Disorders. Clinical and Applied Thrombosis/Hemostasis 22:7, pages 605-616.
Crossref
Crossref
Kehinde O. Obamiro, Leanne Chalmers & Luke R. E. Bereznicki. (2016) A Summary of the Literature Evaluating Adherence and Persistence with Oral Anticoagulants in Atrial Fibrillation. American Journal of Cardiovascular Drugs 16:5, pages 349-363.
Crossref
Crossref
Jan Beyer-Westendorf, Birgit Ehlken & Thomas Evers. (2016) Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace 18:8, pages 1150-1157.
Crossref
Crossref
Craig I. Coleman, Muralikrishna Tangirala & Thomas Evers. (2016) Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States. PLOS ONE 11:6, pages e0157769.
Crossref
Crossref
Jason G. Andrade, Andrew D. Krahn, Allan C. Skanes, Daniel Purdham, Antonio Ciaccia & Sean Connors. (2016) Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention. Canadian Journal of Cardiology 32:6, pages 747-753.
Crossref
Crossref
Marek Jauß, Sibylle Kaiser & Christian Tanislav. (2016) Neue Einsichten durch Real-World-Daten zu oralen Non-Vitamin-K-Antikoagulanzien. InFo Neurologie & Psychiatrie 18:6, pages 46-60.
Crossref
Crossref
A. John Camm, Pierre Amarenco, Sylvia Haas, Susanne Hess, Paulus Kirchhof, Silvia Kuhls, Martin van Eickels & Alexander G.G. Turpie. (2016) XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. European Heart Journal 37:14, pages 1145-1153.
Crossref
Crossref
Walid Amara & Sotiris Antoniou. (2016) Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal Supplements 18:suppl D, pages D1-D6.
Crossref
Crossref
Alan D. Bell, Peter Gross, Michael Heffernan, Yan Deschaintre, Jean-Francois Roux, Daniel M. Purdham & Ashfaq Shuaib. (2016) Appropriate Use of Antithrombotic Medication in Canadian Patients With Nonvalvular Atrial Fibrillation. The American Journal of Cardiology 117:7, pages 1107-1111.
Crossref
Crossref
João Morais & Raffaele De Caterina. (2016) Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants. Cardiovascular Drugs and Therapy 30:2, pages 201-214.
Crossref
Crossref
Jeffrey I. Weitz & John Eikelboom. (2017) Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation. Thrombosis and Haemostasis 115:02, pages 257-270.
Crossref
Crossref
Tomas Forslund, Björn Wettermark & Paul Hjemdahl. (2015) Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. European Journal of Clinical Pharmacology 72:3, pages 329-338.
Crossref
Crossref
Yi Feng Lai, Jun Kai Neo, Mcvin HH Cheen, Ming Chai Kong, Bee Choo Tai & Heng Joo Ng. (2016) Comparison of Medication Adherence and Treatment Persistence between New Oral Anticoagulant and Warfarin among Patients. Annals of the Academy of Medicine, Singapore 45:1, pages 12-17.
Crossref
Crossref
Judith Hecker, Sandra Marten, Loretta Keller, Sindy Helmert, Franziska Michalski, Sebastian Werth, Kurtulus Sahin, Luise Tittl & Jan Beyer-Westendorf. (2017) Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Thrombosis and Haemostasis 115:05, pages 939-949.
Crossref
Crossref
Carlos Martinez, Anja Katholing, Christopher Wallenhorst & Saul Benedict Freedman. (2017) Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. Thrombosis and Haemostasis 115:01, pages 31-39.
Crossref
Crossref
María Monteagudo, Eva Fernández-Díaz, Jorge García-García, Óscar Ayo-Martín, Francisco Hernández-Fernández & Tomás Segura. (2015) Efficacy, safety and tolerability of rivaroxaban for the secondary prevention of stroke in patients with atrial fibrillation in clinical practice. Future Neurology 10:6, pages 529-536.
Crossref
Crossref
Carmen Suárez Fernández, Francesc Formiga, Miguel Camafort, Jose María Cepeda Rodrigo, Jesús Díez-Manglano, Antonio Pose Reino, Gregorio Tiberio & Jose María Mostaza. (2015) Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. BMC Cardiovascular Disorders 15:1.
Crossref
Crossref
Hiroo Terashi, Tomoko Saitou, Makiko Kobayashi, Youhei Ishimura, Yurie Suzuki, Aya Inoue, Takeshi Taguchi, Haruhisa Katou & Hitoshi Aizawa. (2015) Clinical trial and the real world. Cerebral Blood Flow and Metabolism (Japanese journal of cerebral blood flow and metabolism) 26:2, pages 63-66.
Crossref
Crossref